A Phase 2 interventional study of ARD-101 in Bariatric Surgery, Obesity and Weight Gain, sponsored by Aardvark Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Aardvark Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
This is a Phase 2, open-label study to investigate the safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass). This study has a planned enrollment of 30 subjects (approximately 15 for each preceding surgical procedure) and will be conducted in a single center in the United States.
The study will consist of a Screening Period (up to 28 days), a Treatment Period (28 days), and a Follow-up Period (EOS Visit within 14 days after receiving the last dose of ARD-101). The screening procedures will be initiated upon completion of the informed consent process. Following completion of screening procedures and confirmation of eligibility, subjects will be enrolled to receive ARD-101.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 12 is below the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Aardvark Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Stable or well controlled blood pressure per Investigator's judgement during the Screening Period. Specifically: Vital signs after 10 minutes sitting in a chair (feet on floor, back supported):
i. 95 mmHg \< systolic blood pressure (SBP) \<160 mmHg, ii. 45 mm Hg \< diastolic blood pressure (DBP) \<100 mm Hg, iii. 40 bpm \< heart rate (HR) \<100 bpm.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 200 mg of ARD-101, twice daily for 28 days
Drug: ARD-101
Twice daily, oral administration
Relative Change in Body Weight (%)
The percent total weight change at the end of treatment from baseline
Time frame: Baseline and Day 28
Incidence of Treatment-emergent Adverse Events (TEAE)
The incidence of treatment-emergent adverse events (TEAE) during the treatment period
Time frame: Days 1-28
Change in Blood Lipid Concentrations
The change in blood lipid concentrations (total cholesterol, triglyceride, high density lipoprotein cholesterol, and low-density lipoprotein cholesterol) at the end of treatment from the baseline
Time frame: Run-in Visit (baseline), Day 28
Change in Waist Circumference
The change in waist circumference from baseline to end of treatment
Time frame: Baseline and Day 28
Change in Hemoglobin A1c
The change in glycated hemoglobin (HbA1c) at the end of treatment from the baseline
Time frame: Screening (baseline), Day 28
Categorical Weight Loss
Proportion of subjects who lose \< 5% and ≥ 5% initial weight
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of Glucagon-like Peptide (GLP)-1 (Pmol) During Mixed-Meal Tolerance Test (MMTT) at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of glucagon-like peptide (GLP)-1 (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for mixed-meal tolerance test (MMTT) at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Cholecystokinin (CCK) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of cholecystokinin (CCK) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Peptide YY (PYY) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of peptide YY (PYY) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Amylin (Pmol) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of amylin (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Glucose-dependent Insulinotropic Polypeptide (GIP) (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of glucose-dependent insulinotropic polypeptide (GIP) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Ghrelin (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of ghrelin (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Leptin (ng/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of leptin (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Adiponectin (mcg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of adiponectin (mcg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Circulating Levels of Glucagon (pg/mL) During MMTT at Baseline and on Day 28, and Prior to and Post Dosing on Day 1
Circulating levels of glucagon (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Time frame: Run-in Visit (baseline), Day 1, Day 28
Serum Levels of Glucose (mg/dL) During MMTT at Baseline and on Day 28
Serum levels of glucose (mg/dL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Time frame: Run-in Visit (baseline), Day 28
Serum Levels of Insulin (uIU/mL) During MMTT at Baseline and on Day 28
Serum levels of insulin (uIU/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Time frame: Run-in Visit (baseline), Day 28
Serum Levels of C-peptide (ng/mL) During MMTT at Baseline and on Day 28
Serum levels of C-peptide (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Time frame: Run-in Visit (baseline), Day 28
Serum Levels of Free Fatty Acids During MMTT at Baseline and on Day 28
Serum levels of free fatty acids (FFA) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of Interleukin (IL)-1 Beta (pg/mL) During MMTT
Circulating levels of interleukin (IL)-1 beta (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of IL-6 (pg/mL) During MMTT
Circulating levels of IL-6 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of IL-10 (pg/mL) During MMTT
Circulating levels of IL-10 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of IL-12 p40 (pg/mL) During MMTT
Circulating levels of IL-12 p40 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of IL-12 p70 (pg/mL) During MMTT
Circulating levels of IL-12 p70 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of IL-17 (pg/mL) During MMTT
Circulating levels of IL-17 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of Tumor Necrosis Factor (TNF)-Alpha (pg/mL) During MMTT
Circulating levels of tumor necrosis factor (TNF)-alpha (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Circulating Levels of C Reactive Protein (CRP) (mg/L) During MMTT
Circulating levels of C reactive protein (CRP) (mg/L) at run in visit and end of treatment (day 28) performed during the MMTT
Time frame: Run-in Visit (baseline), Day 28
Body Fat Percentage
Body fat percentage measured by bioelectrical impedance scale
Time frame: Run-in Visit (baseline), Days 1-28
Change in the Percentage of Liver Fat Content
Change in the percentage of liver fat content assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)
Time frame: Run-in Visit (baseline), Day 28
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
The change in homeostatic model assessment for insulin resistance (HOMA-IR) at the end of treatment from the baseline
Time frame: Run-in Visit (baseline), Day 28
Change in Fasting Blood Glucose
The change in fasting blood glucose at the end of treatment from the baseline
Time frame: Run-in Visit (baseline), Day 28
Change in Serum Bile Acids
Change in serum bile acids at the end of treatment compared to the baseline
Time frame: Run-in Visit (baseline), Day 28
Phenotypic Taste Test
Phenotypic taste test (using commercially available test strips) at baseline
Time frame: Run-in Visit (baseline)
Control of Eating and Food Cravings
Control of eating and food craving assessed by the Control of Eating Questionnaire (CoEQ), which is a 21-item questionnaire designed to assess the intensity and type of food cravings and subjective sensations of appetite and mood according to an individual's experience over the last 7 days. Items on the CoEQ are assessed by 100-mm visual analogue scales (VAS). Subjects will mark their level with a vertical line on the horizontal line of the VAS scale. The numerical value will start at 1.0 cm and end 10.0 cm. Use a ruler to determine the numerical value (to the tenth decimal) associated with the line marked by subjects. Higher score indicates less control of eating and food cravings.
Time frame: Screening, Days 1, 15, and 28
Change in Indirect Calorimetry
Change in indirect calorimetry between Day 1 and Day 28
Time frame: Day 1, Day 28
Area Under the Curve (AUC) of Serum Level of Glucose (mg/dL) During MMTT
Changes in AUC of serum level of glucose (mg/dL) during MMTT between baseline and Day 28
Time frame: Run-in Visit (baseline), Day 28
Area Under the Curve (AUC) of Serum Level of Insulin (uIU/mL) During MMTT
Changes in AUC of serum level of insulin (uIU/mL) during MMTT between baseline and Day 28
Time frame: Run-in Visit (baseline), Day 28
Area Under the Curve (AUC) of Serum Level of C-peptide (ng/mL) During MMTT
Changes in AUC of serum levels of C-peptide (ng/mL) during MMTT between baseline and Day 28
Time frame: Run-in Visit (baseline), Day 28
Changes in Fecal Microbial Species and Their Relative Abundance
Changes in fecal microbial species and their relative abundance assessed by 16S rRNA gene sequencing
Time frame: Day 1, Day 28
| Milestone | ARD-101 |
|---|---|
| Started | 12 |
| Completed | 11 |
| Not completed | 1 |
| Withdrew: Lost to follow-up | 1 |
The percent total weight change at the end of treatment from baseline
| Percent Change | ARD-101 |
|---|---|
| Relative Change in Body Weight (%) | 0.033 ± 1.515 |
The incidence of treatment-emergent adverse events (TEAE) during the treatment period
| Participants | ARD-101 |
|---|---|
| Incidence of Treatment-emergent Adverse Events (TEAE) | 6 |
The change in blood lipid concentrations (total cholesterol, triglyceride, high density lipoprotein cholesterol, and low-density lipoprotein cholesterol) at the end of treatment from the baseline
| mg/dL | ARD-101 |
|---|---|
| Total Cholesterol | -0.73 ± 18.23 |
| Triglyceride | 2.09 ± 32.14 |
| High density lipoprotein cholesterol | -0.82 ± 9.36 |
| Low-density lipoprotein cholesterol | -0.36 ± 15.58 |
The change in waist circumference from baseline to end of treatment
| Centimeters | ARD-101 |
|---|---|
| Change in Waist Circumference | -0.7 ± 1.03 |
The change in glycated hemoglobin (HbA1c) at the end of treatment from the baseline
| Percentage | ARD-101 |
|---|---|
| Change in Hemoglobin A1c | 0.04 ± 0.17 |
Proportion of subjects who lose \< 5% and ≥ 5% initial weight
Results for this outcome have not been posted.
Circulating levels of glucagon-like peptide (GLP)-1 (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for mixed-meal tolerance test (MMTT) at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of cholecystokinin (CCK) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of peptide YY (PYY) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of amylin (pmol) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of glucose-dependent insulinotropic polypeptide (GIP) (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of ghrelin (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of leptin (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of adiponectin (mcg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Circulating levels of glucagon (pg/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28, and pre-dosing and 1 and 2 hours post the first dosing on day 1.
Results for this outcome have not been posted.
Serum levels of glucose (mg/dL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Results for this outcome have not been posted.
Serum levels of insulin (uIU/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Results for this outcome have not been posted.
Serum levels of C-peptide (ng/mL) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Results for this outcome have not been posted.
Serum levels of free fatty acids (FFA) prior to (negative timepoints) and post (positive timepoints) the Ensure meal given for MMTT at baseline (run-in visit) and on day 28.
Results for this outcome have not been posted.
Circulating levels of interleukin (IL)-1 beta (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of IL-6 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of IL-10 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of IL-12 p40 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of IL-12 p70 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of IL-17 (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of tumor necrosis factor (TNF)-alpha (pg/mL) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Circulating levels of C reactive protein (CRP) (mg/L) at run in visit and end of treatment (day 28) performed during the MMTT
Results for this outcome have not been posted.
Body fat percentage measured by bioelectrical impedance scale
Results for this outcome have not been posted.
Change in the percentage of liver fat content assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF)
Results for this outcome have not been posted.
The change in homeostatic model assessment for insulin resistance (HOMA-IR) at the end of treatment from the baseline
Results for this outcome have not been posted.
The change in fasting blood glucose at the end of treatment from the baseline
Results for this outcome have not been posted.
Change in serum bile acids at the end of treatment compared to the baseline
Results for this outcome have not been posted.
Phenotypic taste test (using commercially available test strips) at baseline
Results for this outcome have not been posted.
Control of eating and food craving assessed by the Control of Eating Questionnaire (CoEQ), which is a 21-item questionnaire designed to assess the intensity and type of food cravings and subjective sensations of appetite and mood according to an individual's experience over the last 7 days. Items on the CoEQ are assessed by 100-mm visual analogue scales (VAS). Subjects will mark their level with a vertical line on the horizontal line of the VAS scale. The numerical value will start at 1.0 cm and end 10.0 cm. Use a ruler to determine the numerical value (to the tenth decimal) associated with the line marked by subjects. Higher score indicates less control of eating and food cravings.
Results for this outcome have not been posted.
Change in indirect calorimetry between Day 1 and Day 28
Results for this outcome have not been posted.
Changes in AUC of serum level of glucose (mg/dL) during MMTT between baseline and Day 28
Results for this outcome have not been posted.
Changes in AUC of serum level of insulin (uIU/mL) during MMTT between baseline and Day 28
Results for this outcome have not been posted.
Changes in AUC of serum levels of C-peptide (ng/mL) during MMTT between baseline and Day 28
Results for this outcome have not been posted.
Changes in fecal microbial species and their relative abundance assessed by 16S rRNA gene sequencing
Results for this outcome have not been posted.
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ARD-101 | 0/12 (0%) | 0/12 (0%) | 6/12 (50%) |
| Event | ARD-101 |
|---|---|
| Mild NauseaGastrointestinal disorders | 2/12 |
| Mild EmesisGastrointestinal disorders | 1/12 |
| Mild Common ColdInfections and infestations | 1/12 |
| Mild HeadacheNervous system disorders | 1/12 |
| Mild ConstipationGastrointestinal disorders | 1/12 |
| Mild Heart BurnGastrointestinal disorders | 1/12 |
| Mild HypoglycemiaEndocrine disorders | 1/12 |
| Mild COVID-19Infections and infestations | 1/12 |
| Mild DyspepsiaGastrointestinal disorders | 1/12 |
Patients who completed treatment of ARD-101
| Age, Continuous(years) | ARD-101 |
|---|---|
| Mean | 41 ± 11 |
| Sex: Female, Male(Participants) | ARD-101 |
|---|---|
| Female | 11 |
| Male | 0 |
| Ethnicity (NIH/OMB)(Participants) | ARD-101 |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | ARD-101 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 9 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Weight(Kilograms) | ARD-101 |
|---|---|
| Mean | 117.9 ± 21.8 |
| Body Mass Index (BMI)(kg/m^2) | ARD-101 |
|---|---|
| Mean | 42.7 ± 4.98 |
| Height(Centimeter) | ARD-101 |
|---|---|
| Mean | 165.6 ± 9.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2022 to primary completion in Feb 2023, 11 months.
Results were first posted in Nov 2024, 1 year 9 months after primary completion.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denatonium acetate monohydrate
Aardvark Therapeutics, Inc.